FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022253175> ?p ?o ?g. }

• W2022253175 abstract "Recently, a new slow-release (SR) formulation of lanreotide (LAN) comprising 60 mg of the drug incorporated in microspheres of biodegradable polymers (SR-LAN 60) has become available. The aim of our study was to assess the effectiveness of SR-LAN 60, administered every 21 to 28 days, as well as its tolerability in the long-term treatment of acromegalic patients treated with SR-LAN 30. Twenty patients with acromegaly (10 males and 10 females) were enrolled in this open study. Thirteen patients had undergone surgery, but with incomplete resection of the pituitary tumor. All patients, treated with intramuscular (IM) SR-LAN 30 injections every 10 days for 12 to 24 months, started SR-LAN 60 (Ipsen-Beaufour, Milan, Italy) administration 10 days after the last injection of SR-LAN 30. Growth hormone (GH) levels were determined on the day of the first injection of SR-LAN 60, and 10, 20, and 30 days after. According to the GH levels reached on day 30, patients received SR-LAN 60 every 28 days if GH levels were below 2.5 microg/L (group A) and every 21 days if GH levels were above 2.5 microg/L (group B). In group A, after the 8th month, SR-LAN 60 treatment resulted in well-controlled GH levels in 9 of 10 patients in comparison to SR-LAN 30 treatment every 10 days (6 of 10 patients). Normal age-adjusted insulin-like growth factor-I (IGF-I) levels were achieved in 4 of 10 patients, as in treatment with SR-LAN 30. In group B, SR-LAN 60 treatment resulted in well-controlled GH levels in 4 of 10 patients, as in treatment with SR-LAN 30 every 10 days. Normal age-adjusted IGF-I levels were achieved in 3 of 10 patients after SR-LAN 60 in comparison to SR-LAN 30 treatment every 10 days (1 of 10 patients). During SR-LAN 60 therapy, an improvement was also observed in signs and symptoms of active acromegaly and no relevant side effects were detected. In conclusion, this study shows that SR-LAN 60 treatment is able to induce a good control of circulating GH and IGF-I levels in most acromegalic patients. The first injections of SR-LAN 60 are very helpful in predicting the optimal long-term injection frequency. Patients on SR-LAN 30 can be safely and effectively shifted to SR-LAN 60." @default.
• W2022253175 created "2016-06-24" @default.
• W2022253175 creator A5009957681 @default.
• W2022253175 creator A5012740387 @default.
• W2022253175 creator A5041145056 @default.
• W2022253175 creator A5046942308 @default.
• W2022253175 creator A5048100872 @default.
• W2022253175 creator A5061346075 @default.
• W2022253175 creator A5061577134 @default.
• W2022253175 creator A5070469478 @default.
• W2022253175 creator A5075228434 @default.
• W2022253175 creator A5084783017 @default.
• W2022253175 date "2002-03-01" @default.
• W2022253175 modified "2023-09-30" @default.
• W2022253175 title "Efficacy and safety of the new 60-mg formulation of the long-acting somatostatin analog lanreotide in the treatment of acromegaly" @default.
• W2022253175 cites W135455108 @default.
• W2022253175 cites W1966058349 @default.
• W2022253175 cites W1967074705 @default.
• W2022253175 cites W1967226362 @default.
• W2022253175 cites W1975874471 @default.
• W2022253175 cites W1989662643 @default.
• W2022253175 cites W2010772266 @default.
• W2022253175 cites W2021422677 @default.
• W2022253175 cites W2042044149 @default.
• W2022253175 cites W2042546360 @default.
• W2022253175 cites W2064092633 @default.
• W2022253175 cites W2073728914 @default.
• W2022253175 cites W2083098067 @default.
• W2022253175 cites W2083857950 @default.
• W2022253175 cites W2087391960 @default.
• W2022253175 cites W2114607990 @default.
• W2022253175 cites W2116642079 @default.
• W2022253175 cites W2118164366 @default.
• W2022253175 cites W2120902410 @default.
• W2022253175 cites W2121166290 @default.
• W2022253175 cites W2124074950 @default.
• W2022253175 cites W2125281089 @default.
• W2022253175 cites W2134166265 @default.
• W2022253175 cites W2137711231 @default.
• W2022253175 cites W2152997319 @default.
• W2022253175 cites W2164303686 @default.
• W2022253175 cites W248138904 @default.
• W2022253175 doi "https://doi.org/10.1053/meta.2002.30526" @default.
• W2022253175 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11887179" @default.
• W2022253175 hasPublicationYear "2002" @default.
• W2022253175 type Work @default.
• W2022253175 sameAs 2022253175 @default.
• W2022253175 citedByCount "19" @default.
• W2022253175 countsByYear W20222531752012 @default.
• W2022253175 countsByYear W20222531752015 @default.
• W2022253175 countsByYear W20222531752018 @default.
• W2022253175 countsByYear W20222531752020 @default.
• W2022253175 crossrefType "journal-article" @default.
• W2022253175 hasAuthorship W2022253175A5009957681 @default.
• W2022253175 hasAuthorship W2022253175A5012740387 @default.
• W2022253175 hasAuthorship W2022253175A5041145056 @default.
• W2022253175 hasAuthorship W2022253175A5046942308 @default.
• W2022253175 hasAuthorship W2022253175A5048100872 @default.
• W2022253175 hasAuthorship W2022253175A5061346075 @default.
• W2022253175 hasAuthorship W2022253175A5061577134 @default.
• W2022253175 hasAuthorship W2022253175A5070469478 @default.
• W2022253175 hasAuthorship W2022253175A5075228434 @default.
• W2022253175 hasAuthorship W2022253175A5084783017 @default.
• W2022253175 hasConcept C126322002 @default.
• W2022253175 hasConcept C126894567 @default.
• W2022253175 hasConcept C134018914 @default.
• W2022253175 hasConcept C141071460 @default.
• W2022253175 hasConcept C197934379 @default.
• W2022253175 hasConcept C2776297358 @default.
• W2022253175 hasConcept C2776694085 @default.
• W2022253175 hasConcept C2777433750 @default.
• W2022253175 hasConcept C2778375690 @default.
• W2022253175 hasConcept C2779609023 @default.
• W2022253175 hasConcept C2781025020 @default.
• W2022253175 hasConcept C2984496839 @default.
• W2022253175 hasConcept C71315377 @default.
• W2022253175 hasConcept C71924100 @default.
• W2022253175 hasConcept C90924648 @default.
• W2022253175 hasConceptScore W2022253175C126322002 @default.
• W2022253175 hasConceptScore W2022253175C126894567 @default.
• W2022253175 hasConceptScore W2022253175C134018914 @default.
• W2022253175 hasConceptScore W2022253175C141071460 @default.
• W2022253175 hasConceptScore W2022253175C197934379 @default.
• W2022253175 hasConceptScore W2022253175C2776297358 @default.
• W2022253175 hasConceptScore W2022253175C2776694085 @default.
• W2022253175 hasConceptScore W2022253175C2777433750 @default.
• W2022253175 hasConceptScore W2022253175C2778375690 @default.
• W2022253175 hasConceptScore W2022253175C2779609023 @default.
• W2022253175 hasConceptScore W2022253175C2781025020 @default.
• W2022253175 hasConceptScore W2022253175C2984496839 @default.
• W2022253175 hasConceptScore W2022253175C71315377 @default.
• W2022253175 hasConceptScore W2022253175C71924100 @default.
• W2022253175 hasConceptScore W2022253175C90924648 @default.
• W2022253175 hasLocation W20222531751 @default.
• W2022253175 hasLocation W20222531752 @default.
• W2022253175 hasOpenAccess W2022253175 @default.
• W2022253175 hasPrimaryLocation W20222531751 @default.
• W2022253175 hasRelatedWork W108281130 @default.
• W2022253175 hasRelatedWork W123434114 @default.
• W2022253175 hasRelatedWork W1981382809 @default.

• next